CME Bridge List

<< Back to CME Activities
Show : Per page of 4

Visualizing Updates in Melanoma Management: Novel Combinations, Development, and Best Practices in Sequencing Therapy

This program will inform clinicians of immunopathological assessment of melanoma especially in relation to patterns of resistance, the advantages of novel combination immunotherapies in the treatment of melanoma, and the evaluation of associated toxicities and their management in patients.

RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024

Learn More & View Event »

Use of Immunotherapy for Advanced Melanoma: Integrating Patient-Centric and Multidisciplinary Strategies

This interactive enduring activity is designed to help you optimize the development of treatment plans for your patients with advanced melanoma. Specifically, this program will provide a comprehensive review of the latest data on current and emerging immunotherapy approaches, and of effective strategies to mitigate and manage immunotherapy-associated adverse events. It will also share, expert appraisals of new treatment approaches through multiple clinical case scenarios, illustrative animations, and didactic presentations. Our goal is also to emphasize the importance of shared decision making while maintaining the patient’s well-being.

RELEASED DATE: June 28, 2024
EXPIRATION DATE: June 28, 2025

Learn More & View Event »

Non-Melanoma Skin Cancers: Immunotherapy Strategies Across the Spectrum of Disease

This program will inform clinicians of the rationale for use of immunotherapy in cutaneous squamous cell carcinoma (cSCC), including the reasoning behind investigations of its use in the neoadjuvant and adjuvant settings. Through the immersive 3D animations, clinicians will be exposed to current perspectives on the pathophysiology of early cSCC, how immunotherapy before and/or after surgery may improve outcomes, and available data from clinical study of neoadjuvant immunotherapy for cSCC.

RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024

Learn More & View Event »

An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies

This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician's assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma; assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma; and recognize safety data with combination immunotherapy approaches in advanced melanoma.

RELEASED DATE: March 03, 2023
EXPIRATION DATE: March 03, 2024

Learn More & View Event »
Scroll to Top